UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
____________________
FORM 8-K
____________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): February 2, 2017
____________________
| Immunomedics, Inc. |
| (Exact Name of Registrant as Specified in its Charter) |
|
| | | |
| Delaware | 000-12104 | 61-1009366 |
(State or Other Jurisdiction
of Incorporation) | (Commission File Number) | (IRS Employer Identification No.) |
| | | |
| | |
| 300 The American Road, Morris Plains, New Jersey | 07950 |
| (Address of principal executive offices) | (Zip Code) |
| | | |
(973) 605-8200
(Registrant’s telephone number,
including area code |
| | | |
Not applicable
(Former Name or Former Address, if Changed Since Last Report) |
____________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01. Other events
On February 2, 2017, Immunomedics, Inc. issued a press release titled “Immunomedics Mails Letter to Stockholders Highlighting Strength of New Board and Deep Engagement in Robust, Value-Creating Strategic and CMC Processes.” The full text of the press release is attached to this current report on Form 8-K as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No. | Description of Exhibit |
| 99.1 | Press Release of Immunomedics, Inc., dated February 2, 2017, titled “Immunomedics Mails Letter to Stockholders Highlighting Strength of New Board and Deep Engagement in Robust, Value-Creating Strategic and CMC Processes” |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
IMMUNOMEDICS, INC.
By:/s/ Michael R. Garone
Name: Michael R. Garone
Title: Vice President, Finance and Chief Financial Officer
Date: February 2, 2017
Exhibit Index
Exhibit
Number | | Description |
| 99.1 | | Press Release of Immunomedics, Inc., dated February 2, 2017, titled “Immunomedics Mails Letter to Stockholders Highlighting Strength of New Board and Deep Engagement in Robust, Value-Creating Strategic and CMC Processes” |
